Table 2.

Multivariable-adjusted differences between placebo and paliperidone in the primary outcome (PSP) and mediators (WG, PANSS, and SAS score)

	PSP	PANSS	WG	SAS
Paliperidone 3 mg	8.42 (4.21, 12.64)	−3.47(−6.47, −0.47)	0.02 (0.01, 0.03)	0.14 (−0.19, 0.48)
Paliperidone 9 mg	9.74 (6.12, 13.35)	−3.91(−6.77, −1.06)	0.03 (0.02, 0.05)	0.71 (0.27, 1.16)
Paliperidone 15 mg	13.03 (9.21, 16.84)	−4.78(−7.86, −1.71)	0.04 (0.02, 0.05)	0.68 (0.24, 1.13)
Placebo	Ref	Ref	Ref	Ref

All models adjusted for age, sex, race, country, relative day of disease onset, total PANSS score at baseline, PSP score at baseline, BARS score at baseline, SAS score at baseline, BMI at baseline. We report pooled estimates (pooled confidence intervals) from 50 multiple imputations